Orchid Health is building whole-genome sequencing (WGS) for IVF embryos, fundamentally expanding what parents and clinicians can understand about genetic risk before implantation. By sequencing the full genome rather than screening for a limited set of conditions, Orchid provides a step-change in the amount and quality of information available during family planning.

The company integrates directly into fertility clinic workflows, combining clinical genetics, data infrastructure, and AI-driven interpretation to deliver results that are actionable, compliant, and practical to use. Orchid is not positioning genomics as research — it is making it part of standard care.

Orchid is led by Noor Siddiqui, a founder with rare conviction in a sensitive and consequential domain. The company has been covered by WIRED and The Washington Post and is working with fertility clinics across the country.